Human IFN has previously been used to treat several viral infections (Lokugamage et al., 2020; Strayer et al., 2014) and clinical trials against SARS-CoV-2 are ongoing (ClinicalTrials.gov number: NCT04315948, NCT04385095, and NCT04492475). The gene discussed is IFNA1; the disease is viral infectious disease.